The FDA advises health care providers to counsel patients receiving alemtuzumab on symptoms related to stroke and arterial dissection.
Epstein-Barr virus and Kaposi's sarcoma herpesvirus can activate and lead to the growth of cancerous cells.
Top news of the day from across the health care landscape.
Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.
New platform would allow health care providers in developing nations to perform easy HIV testing and monitoring.
The drug’s application was designated for fast track and priority review, as well as orphan product status.
Rituximab-abbs (Truxima, Celltrion) is the fifteenth biosimilar approved by the FDA and the sixth biosimilar approved in 2018 thus far.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.